Neoplastic Process
Gilead’s Magrolimab Linked to Increased Risk of Death in Blood Cancer Patients
Gilead, Magrolimab, Blood Cancer, Increased Risk of Death, ENHANCE Study
Geron’s Rytelo Receives FDA Approval for Lower-Risk Myelodysplastic Syndromes Treatment
Geron, Rytelo, FDA Approval, Blood Cancer, Myelodysplastic Syndromes, Telomerase Inhibitor, Imetelstat
AbbVie Achieves Early Return on Investment with $10 Billion Immunogen Acquisition Following Phase II Ovarian Cancer Success
AbbVie, Immunogen, Ovarian Cancer, Phase II Trial, Return on Investment (ROI), Antibody-Drug Conjugate (ADC), Elahere
ASCO: AbbVie Revamps ADC Portfolio to Replace Chemotherapy
ASCO, AbbVie, ADCs, Chemotherapy, Rova-T, Teliso-V, Cancer Treatment
AbbVie’s $10.1 Billion ImmunoGen Acquisition Bears Fruit with Elahere’s Mid-Stage Success in Ovarian Cancer Treatment
AbbVie, ImmunoGen, Elahere, Ovarian Cancer, Antibody-Drug Conjugate (ADC), Clinical Trial, Acquisition, Oncology
ITM Secures €188 Million to Enhance Radiopharmaceutical Pipeline and Strengthen Medical Radioisotope Manufacturing
ITM Isotope Technologies Munich, radiopharmaceutical biotech, Temasek, BlackRock, Qatar Investment Authority, medical radioisotopes, Lutetium-177, Actinium-225, cancer pipeline, gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
RYBREVANT: A Breakthrough in Lung Cancer Treatment
RYBREVANT, lung cancer, EGFR mutations, subcutaneous administration, intravenous administration, infusion-related reactions, survival rate, non-small cell lung cancer (NSCLC)
GSK Strengthens Case for Blenrep’s Return in Multiple Myeloma Treatment
Blenrep, GSK, multiple myeloma, ASCO, DREAMM-8, DREAMM-7, Velcade, Darzalex, Pomalyst, CAR-T therapy, antibody-drug conjugate
Jazz Pharmaceuticals Presents Groundbreaking HER2 Biliary Tract Cancer Data Ahead of FDA Decision
Jazz Pharmaceuticals, HER2, Biliary Tract Cancer, FDA Decision, Zanidatamab, Priority Review
Sanofi’s Sarclisa Achieves First-in-Class Win, Poised to Surpass J&J in Multiple Myeloma Treatment
Sarclisa, Sanofi, multiple myeloma, J&J, ASCO, IMROZ study, anti-CD38 therapy, VRd, transplant-ineligible patients